- 
                                    
- 
                                            Overview
                                            
- 
                                                    
                                                    
Please contact us at for specific academic pricing.
Background
SU14813 is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), Kit, and fms-like tyrosine kinase 3 (FLT-3).
 
 - 
                                                    
                                                    
 - Properties
 
 - 
                                            Overview